An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Jianqing Lin, Aileen Deng, Jean Hoffman-Censits, Geoffrey Gibney, Terry Hyslop, Brooke Miller, Deborah Kilpatrick, Serge Jabbour, William Kevin Kelly

Research output: Contribution to journalArticle

Abstract

New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.

Original languageEnglish (US)
Pages (from-to)192-195
Number of pages4
JournalCancer Treatment Communications
Volume4
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Drug Therapy
Somatostatin Receptors
Phosphatidylinositol 3-Kinase
Sirolimus
Therapeutics
Phosphatidylinositol 3-Kinases
Clinical Trials
Everolimus
pasireotide
Research

Keywords

  • Castrate-resistant
  • Everolimus
  • Pasireotide
  • Phase II
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Cite this

An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients. / Lin, Jianqing; Deng, Aileen; Hoffman-Censits, Jean; Gibney, Geoffrey; Hyslop, Terry; Miller, Brooke; Kilpatrick, Deborah; Jabbour, Serge; Kevin Kelly, William.

In: Cancer Treatment Communications, Vol. 4, 01.01.2015, p. 192-195.

Research output: Contribution to journalArticle

Lin, Jianqing ; Deng, Aileen ; Hoffman-Censits, Jean ; Gibney, Geoffrey ; Hyslop, Terry ; Miller, Brooke ; Kilpatrick, Deborah ; Jabbour, Serge ; Kevin Kelly, William. / An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients. In: Cancer Treatment Communications. 2015 ; Vol. 4. pp. 192-195.
@article{1d60caad9f6c4926b3b60d9385dff19e,
title = "An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-na{\"i}ve prostate cancer patients",
abstract = "New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-na{\"i}ve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50{\%} PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.",
keywords = "Castrate-resistant, Everolimus, Pasireotide, Phase II, Prostate cancer",
author = "Jianqing Lin and Aileen Deng and Jean Hoffman-Censits and Geoffrey Gibney and Terry Hyslop and Brooke Miller and Deborah Kilpatrick and Serge Jabbour and {Kevin Kelly}, William",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ctrc.2015.11.003",
language = "English (US)",
volume = "4",
pages = "192--195",
journal = "Cancer Treatment and Research Communications",
issn = "2213-0896",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

AU - Lin, Jianqing

AU - Deng, Aileen

AU - Hoffman-Censits, Jean

AU - Gibney, Geoffrey

AU - Hyslop, Terry

AU - Miller, Brooke

AU - Kilpatrick, Deborah

AU - Jabbour, Serge

AU - Kevin Kelly, William

PY - 2015/1/1

Y1 - 2015/1/1

N2 - New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.

AB - New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.

KW - Castrate-resistant

KW - Everolimus

KW - Pasireotide

KW - Phase II

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84947923941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947923941&partnerID=8YFLogxK

U2 - 10.1016/j.ctrc.2015.11.003

DO - 10.1016/j.ctrc.2015.11.003

M3 - Article

AN - SCOPUS:84947923941

VL - 4

SP - 192

EP - 195

JO - Cancer Treatment and Research Communications

JF - Cancer Treatment and Research Communications

SN - 2213-0896

ER -